QL
RNAC icon

Quarry LP’s Cartesian Therapeutics RNAC Stock Holding History

Quarry LP’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156 Buy
+15
New +$111 ﹤0.01% 2314

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Quarry LP's RNAC Position: Q2 2026 in Review

Quarry LP opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 15 shares worth $156. The stake represents ﹤0.01% of the portfolio and ranks #2314 among its holdings.

95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Quarry LP held 15 shares of Cartesian Therapeutics worth $156 as of Q2 2026.
  • Cartesian Therapeutics was a new Quarry LP position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Quarry LP's portfolio in Q2 2026, its #2314 holding.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.